Sermorelin

Sermorelin

Sermorelin

Special Price $20.99 was $29.99
In stock
SKU
Sermorelin

Sermorelin is a synthetic peptide developed to be a functional analogy of growth hormone releasing hormone (GHRH). In fact, Sermorelin is a 29 amino acid segment of endogenous GHRH that retains the same spectrum of function as its native counterpart1. Sermorelin acts on the anterior pituitary gland in order to stimulate growth hormone (GH) production in short pulses2. With its very short half-life, Sermorelin elicits a GH release profile that closely reflects what occurs in nature.

Description

Sermorelin is a synthetic peptide developed to be a functional analogy of growth hormone releasing hormone (GHRH). In fact, Sermorelin is a 29 amino acid segment of endogenous GHRH that retains the same spectrum of function as its native counterpart1. Sermorelin acts on the anterior pituitary gland in order to stimulate growth hormone (GH) production in short pulses2. With its very short half-life, Sermorelin elicits a GH release profile that closely reflects what occurs in nature.

Sermorelin, usually in combination with other growth hormone secretagogues, is reported to be an apt agent for the stimulation of short-term GH and IGF-1 release3. High levels of GH and IGF-1 have been shown to result in the promotion of lean body mass, enhanced strength, increased appetite, and an improved quality of sleep in animal test subjects4. Sermorelin has been identified as an agent to counter the effects of aging and to substitute GH in the case of adult onset GH insufficiency in animal trials5.

Product Comparison

Sermorelin is very similar in structure and function to the synthetic GHRH analogy CJC-1295. CJC-1295 no DAC possesses substitutions at four amino acid sites that allow a short-term escape from enzymatic degradation and makes it possible to experience an additive effect on GH levels when administering doses in close succession6. Sermorelin lacks this functionality on its own, as doses separated by short periods of time have been shown not to elicit cumulative effects on GH levels. Though, in combination with a growth hormone secretagogue like Ipamorelin, which acts to dampen the counteractive production of somastatin, Sermorelin has been found to be very effective at releasing large amounts of GH7.

CJC-1295 with DAC is similar in structure and function to Sermorelin, but the inclusion of the DAC group acts to increase its half-life and therefore acts to elicit sustained GH release8.

Synonyms: Sermorelin acetate hydrate; Sermorelin GRF 1-29; GRF 1-29; GRF 1-29 NH2; Geref®;

Peer-Reviewed Sources:

(1) Prakash, Amitabh, and Karen L. Goa. "Sermorelin." BioDrugs 12.2 (1999): 139-157.

(2) Lance, V. A., Murphy, W. A., Sueiras-Diaz, J., & Coy, D. H. (1984). Super-active analogs of growth hormone-releasing factor (1–29)-amide. Biochemical and biophysical research communications, 119(1), 265-272.

(3) Neyzi, O., Yordam, N., Oca, G., Bundak, R., Darendeliler, F., AGikǧoz, E., ... & Calikoglu, A. S. (1993). Growth response to growth hormone‐releasing hormone (1–29)‐NH2 compared with growth hormone. Acta Paediatrica,82(s389), 16-21.

(4) Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J. P., Frohman, L. A., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism, 291(6), E1290-E1294.

(5) Walker, R. F. (2006). Sermorelin: A better approach to management of adult-onset growth hormone insufficiency?. Clinical interventions in aging, 1(4), 307.

(6) Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805.

(7) Raun, K., Hansen, B. S., Johansen, N. L., Thogersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561.

(8) Jette, L., Leger, R., Thibaudeau, K., Benquet, C., Robitaille, M., Pellerin, I., ... & Bridon, D. P. (2005). Human growth hormone-releasing factor (hGRF) 1–29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: Identification of CJC-1295 as a long-lasting GRF analog. Endocrinology,146(7), 3052-3058.

More Information
CAS Number 86168-78-7
PubChem CID 16133753
Molecular Formula C149H246N44OS42S
Residue Sequence H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
Molar Mass 3357.96 g/mol
Specificity Like its naturally occurring analogy GHRH, Sermorelin has an affinity for the GHRH receptor.
Physical Appearance Fine White Lyophilized Powder
Solubility 100 μg/mL sterile diluent (distilled de-ionized water)
Stability Lyophilized protein is to be stored at -20°C. It is recommended to aliquot the reconstituted (dissolved) protein into several discrete vials in order to avoid repeated freezing and thawing. Reconstituted protein can be stored at 4°C.
Source Biosynthetic production
This product is prepared for LABORATORY RESEARCH USE ONLY and may not be used for other purposes.